General Information
Version
6.5
Revision date
2023-10-27
Product name
6-Aminohexanamide
CAS No.
373-04-6
REACH No
A
Emergency telephone
+(47)-22591300, +(47)-21930678
Icons in SDS
Company Information
company name
Merck Life Science AS
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Warning Warning
Hazard statements
H319 Causes serious eye irritation. Reduced Labeling (<= 125 ml) none
Precautionary statements
P264 Wash skin thoroughly after handling. P280 Wear eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 If eye irritation persists: Get medical advice/ attention. none
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Eye irritation (Category 2), H319 For the full text of the H-Statements mentioned in this Section, see Section 16.
